TABLE 3.
Residual human anti-PA AVP-21D9 levels and MTT neutralization titers in sera of rabbits
| Rabbit strain and challenge routea | Wk 1
|
Wk 5
|
Wk 7
|
|||
|---|---|---|---|---|---|---|
| Human PA ELISA result, μg/mlb | MTT neutralization titerc | Human PA ELISA result, μg/ml | MTT neutralization titer | Human PA ELISA result, μg/ml | MTT neutralization titer | |
| DB | ||||||
| Aerosol | 109.7 ± 14.6 | 65,000 ± 24,759 | 13.7 ± 13.3 (12.5)d | 4,450 ± 3,112 (6.9) | 3.6 ± 4.3 (3.3) | 6,933 ± 5,340 (10.7) |
| Intranasal | 106.2 ± 7.8 | 40,000 ± 12,220 | 20.4 ± 6.6 (19.2) | 7,100 ± 2,300 (17.8) | 7.3 ± 3.6 (6.9) | 1,108 ± 217 (2.8) |
| NZ | ||||||
| Aerosol | 82.0 ± 10.4 | 29,333 ± 3,197 | 3.9 ± 4.3 (4.8) | 1,500 ± 891 (5.1) | 0.9 ± 1.2 (1.1) | 920 ± 591 (3.1) |
| Intranasal | 73.1 ± 18.7 | 25,333 ± 5,850 | 2.7 ± 3.2 (3.7) | 1,850 ± 2,114 (7.3) | 1.0 ± 1.4 (1.4) | 1,583 ± 1,423 (6.3) |
a
DB, Dutch-belted dwarf rabbits; NZ, New Zealand White rabbits.
b
Mean residual human anti-PA (AVP-21D9) levels (± standard deviation) in the sera of rabbits at various times postchallenge and dosing.
c
Mean MTT neutralization titers (± standard deviation) of the same sera in protecting J774 cells from lethal toxin challenge.
d
The numbers in parentheses indicate the percentage of the residual serum level of human anti-PA remaining relative to the serum level at 1 week postchallenge.